Pharmaceutical Sector and Pharmacoeconomics

It is a medical product used for the diagnosis, prevention or treatment of life-threatening or disabling rare diseases (rare diseases are defined as diseases that occur in at most 5 out of every 10,000 people in Europe, with life-threatening and disabling consequences).

Over-the-counter (OTC): Some painkillers, stomach medications, vitamins and minerals, which are used for simple ailments that are deemed safe and suitable for use without the need for supervision by healthcare professionals, are drugs that can be purchased without a prescription.

Examining the top six therapeutic categories, which represent 48.4% of the market in terms of value, oncology medications continue to hold the undisputed top spot and have witnessed an increase in share over the last eight years, going from 13.6% to 15.2%.

First, there are the multinational companies, which account for 40–60% of most developed nations’ national markets. These companies are quite international. The smaller, national companies that specialize in selling medications don’t require a lot of R&D. They don’t invest in R&D; instead, they focus mostly on production and commercialization activities. Some firms focus on developing new biotechnologies, and their endeavors encompass everything from finding and creating novel therapeutic molecules to creating innovative drug screening methods and research instruments and technologies in domains such as genomics and bioinformatics

However, the pharmaceutical industry is gradually and steadily facing some challenges. One threat is the rising expense of drug research. Drug companies are presently spending an estimated USD 212 billion per year on research and development (R&D), with that figure predicted to rise to USD 255 billion by 2026. However, this figure is expanding at a slower rate than the availability of prescription pharmaceuticals on the market. This means that major pharmaceutical corporations such as Pfizer, Merck & Co., and others are confronting rising costs, as their output needs to catch up to customer demand.

In-patent drugs: Drugs protected by patents. Out-of-patent drugs (generics): Drugs whose patents have expired.

Clinical trials, which are carried out in multiple phases to assess the drug candidate’s safety and effectiveness in humans, follow the drug development phase: Phase I trials concentrate on dosage and safety in a small number of well participants. Phase II trials assess the medication’s safety and efficacy in a broader patient population with the ailment or condition. Phase III trials usually involve a larger number of participants and provide additional confirmation of the drug’s safety and effectiveness in a variety of patient populations.

The first step in pharmaceutical R&D is drug discovery. This phase involves identifying potential drug candidates through extensive scientific research, often targeting specific disease mechanisms or biological pathways. Techniques such as high-throughput screening, computational modeling, and molecular biology are employed to identify compounds with therapeutic potential. On the other hand, developing new pharmaceutical molecules involves substantial fixed costs. These costs include expenses related to laboratory research (preclinical), clinical trials, regulatory approvals, and manufacturing setup. The process requires significant investment long before any potential returns can be realized.

Post-marketing surveillance is an ongoing procedure that makes sure that information about side effects, medication interactions, and long-term effects is gathered and examined in order to protect patient safety. The decision for firms to invest in the discovery and development of new therapies hinges on the balance between the high costs and the anticipated returns.

Labor and Resources: Highly specialized and skilled labour, sophisticated equipment, and materials are essential, contributing to the high fixed costs. Regulatory Compliance: Navigating the complex regulatory landscape adds to both the financial and time costs of drug development. Market Exclusivity: Patents and exclusivity periods provide a temporary monopoly, allowing companies to recoup their investments by charging higher prices without competition. Market Demand: The potential market size and demand for new therapies significantly impact the expected returns. Drugs addressing widespread or severe conditions typically offer higher returns. Pricing and Reimbursement: The ability to set profitable prices and obtain favorable reimbursement rates from insurers and health systems is crucial.

Availability: This dimension focuses on the physical presence of medicines within a healthcare system. This includes issues such as the availability of essential medicines in healthcare centres, pharmacies and other points of care. Availability also includes supply chain management, ensuring that medicines are constantly stocked and replenished to meet demand. Affordability: Affordability refers to the financial accessibility of drugs to individuals and patients. It includes factors such as the cost of medicines relative to people’s income, the existence of health insurance or financing mechanisms to cover the cost of medicines, and the existence of subsidies or price regulation policies to ensure affordability, especially for essential medicines. Accessibility: Accessibility goes beyond availability and affordability, taking into account geographic and logistical barriers that may prevent individuals from receiving medications when they need them. This dimension includes aspects such as the proximity of healthcare facilities or pharmacies to individuals and patients, transportation infrastructure, and the availability of trained healthcare providers who can prescribe and dispense medications.
Acceptability: Acceptability refers to the cultural, social and psychological factors that may influence people’s willingness or ability to access and use medicines. This dimension includes aspects such as the availability of medications that are compatible with cultural or religious beliefs, language and communication barriers that may affect understanding of and adherence to medication regimens, and the trust individuals have in healthcare providers and the healthcare system as a whole.

Non-communicable diseases (NCDs) are medical conditions or diseases that are not infectious and cannot be transmitted from person to person. They are typically chronic diseases that progress slowly and have long durations.

The Daily Defined Dose is defined as the average maintenance dose per day for a drug when used for its main indication in adults. It is expressed in terms of the drug’s weight (usually grams or milligrams) or units (such as tablets or capsules).

Health Technology Assessment has been the most important institutional regulation in recent years and serves as a way to use pharmaceutical expenditures more effectively through value-based payment. Some countries conduct health technology assessments to evaluate the clinical and cost-effectiveness of new pharmaceuticals before they are approved for reimbursement. HTA processes can affect which pharmaceuticals are covered and at what price, thereby affecting pharmaceutical spending.

In recent years, the reference price system is one of the intervention methods that ensures that pharmaceutical expenditures and prices are determined at an appropriate and acceptable level. In practice, there are two different types of reference pricing systems: internal reference pricing, where comparisons between therapeutically equivalent drugs are made based on domestic prices, and external/international reference pricing, where drug prices are determined according to a group of countries. However, external reference pricing is more important, especially as it strong limits pharmaceutical expenditures. External reference price (Festbeträge) was first used in Germany in 1989. It became widespread after it was put into practice, such as the Netherlands (1991), Norway (1993), Sweden (1993), Denmark (1993), Hungary (1999), Spain (2000), Belgium (2001), Italy (2001). It was adopted by other countries and quickly put into practice. External reference price (ERF), which is implemented as an important expenditure control tool in almost 70% of European countries, has begun to be implemented rapidly in countries outside Europe such as Australia (1990), New Zealand (1993) and British Colombia - Canada (1995).

Under the Ministry of Health, the Turkish Medicines and Medical Devices Agency (TMMDA-Türkiye İlaç ve Tıbbi Cihaz Kurumu) is in charge of pharmaceutical regulation in Türkiye. The TMMDA is in charge of making sure that medications and medical equipment fulfill the required requirements for quality, safety, and efficacy. Before being sold in Turkey, pharmaceutical items must first have marketing authorization from the TMMDA. This entails a thorough examination of the product’s quality, safety, and efficacy data. Applications are assessed by the TMMDA according to international standards compliance, manufacturing procedures, and data from clinical trials. Pre-market assessment and post-market monitoring are steps in the approval process.

A type of comparative economic analysis known as cost-benefit analysis compares and contrasts two or more policy options based on how much they would cost and how they will work out in terms of money. In theory, it ought to consider the preferences of the impacted parties when valuing the interventions’ pertinent costs and results (i.e., the individuals’ willingness to pay).

A type of comparative economic analysis known as cost-consequence analysis compares the relative costs and outcomes of two or more policy options; the results are provided in many meaningful outcomes rather than being summed up in a single metric.

A cost-outcome study (a type of partial evaluation)would examine both the costs and consequences of an intervention but would only evaluate a single course of action (i.e, it would evaluate a single policy option without a formal reference to a comparator scenario). Full economic evaluations are a specific type of health economic analysis that explicitly compare the costs and consequences of the intervention(s) in questions to an alternative course of action, known as the comparator.

A type of comparative economic analysis known as cost-effectiveness analysis compares the relative costs and outcomes of two or more policy alternatives, with the latter evaluated in a single natural unit such as life years gained or disease cases avoided.